Back to top
more

Applied Therapeutics (APLT)

(Real Time Quote from BATS)

$0.46 USD

0.46
282,474

+0.02 (4.38%)

Updated Aug 4, 2025 02:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -17.39% and 18.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of -22.22% and 52.51%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

BeiGene (ONC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Company News for Dec 2, 2024

by Zacks Equity Research

Companies in The News Are: APLT,TGT,WMT,AAPL

Zacks Equity Research

Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More

by Zacks Equity Research

SAVA and APLT tank on pipeline and regulatory setbacks.

Zacks Equity Research

APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDA

by Zacks Equity Research

Applied Therapeutics stock plummets 77% after the FDA issues a CRL for the company's NDA seeking approval for govorestat to treat classic galactosemia.

Zacks Equity Research

Applied Therapeutics (APLT) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Applied Therapeutics (APLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Is Applied Therapeutics (APLT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Applied Therapeutics Inc. (APLT) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.

Zacks Equity Research

Are Medical Stocks Lagging Applied Therapeutics (APLT) This Year?

by Zacks Equity Research

Here is how Applied Therapeutics Inc. (APLT) and CareCloud, Inc. (CCLD) have performed compared to their sector so far this year.

Zacks Equity Research

Is Applied Therapeutics (APLT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Applied Therapeutics Inc. (APLT) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Zacks Equity Research

All You Need to Know About Applied Therapeutics (APLT) Rating Upgrade to Buy

by Zacks Equity Research

Applied Therapeutics (APLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA

by Zacks Equity Research

Applied Therapeutics stock surges 69% as the FDA says that no advisory committee meeting is required to discuss the govorestat NDA for classic galactosemia.

Zacks Equity Research

G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of -5.26% and 4.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why

by Zacks Equity Research

Applied Therapeutics (APLT) surges 124% in a month due to encouraging updates from two separate developmental programs for govorestat to treat different rare neurological indications.

Zacks Equity Research

Bears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Applied Therapeutics Inc. (APLT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase

by Zacks Equity Research

Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.

Zacks Equity Research

Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition

by Zacks Equity Research

Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.

Zacks Equity Research

Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate

by Zacks Equity Research

Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.

Zacks Equity Research

Horizon (HZNP) Begins Enrollment in Alopecia Areata Study

by Zacks Equity Research

Horizon (HZNP) enrolls the first patient in a phase II study evaluating daxdilimab (HZN-7734) for the treatment of alopecia areata.

Zacks Equity Research

Seagen's (SGEN) Stock Up on CEO's Resignation Announcement

by Zacks Equity Research

Seagen's (SGEN) current chief executive officer and president, Clay Siegall, announces his resignation. The company is looking for a new CEO. Stock up.

Zacks Equity Research

Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia

by Zacks Equity Research

The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.

Zacks Equity Research

The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma

by Zacks Equity Research

Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma are part of Zacks top Analyst Blog

Kinjel Shah headshot

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

by Kinjel Shah

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

Zacks Equity Research

Perrigo (PRGO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Zacks Equity Research

Ultragenyx's (RARE) Q1 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.